GlassScriptPhysician profile
Brandon L Huggins
NPI 1962986091
$5,731.15
in general payments reported to CMS, 2019-2025
46 companies · $3,986 in 2025
The $3,986 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.40 · 2023: $128 · 2024: $1,601 · 2025: $3,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,539 · Long Term Medical Supply Or Device Loan: $798 · Education: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,538.95 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $379.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,152.23 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $414.30 | 2022-2025 | Airsupra, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $361.51 | 2024-2025 | Talvey, Darzalex, Erleada |
| E.R. Squibb & Sons, L.L.C. | $340.74 | 2024-2025 | Opdivo, Krazati, Opdualag |
| Incyte Corporation | $283.58 | 2024-2025 | Monjuvi, Jakafi, Zynyz |
| Merck Sharp & Dohme LLC | $274.97 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Pfizer INC. | $214.61 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.60 | 2024-2025 | Ninlaro, Alunbrig, Vpriv |
| Celgene Corporation | $174.20 | 2024-2025 | Reblozyl, Opdualag |
| Genzyme Corporation | $168.84 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $147.95 | 2025 | Libtayo, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $104.51 | 2025 | |
| Abbvie INC. | $104.09 | 2024-2025 | |
| Sanofi US Services INC. | $103.88 | 2025 | |
| Aveo Pharmaceuticals, INC. | $103.24 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $100.24 | 2024-2025 | Rytelo |
| Seagen INC. | $99.99 | 2025 | |
| Lilly USA, LLC | $97.41 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Springworks Therapeutics, INC. | $96.77 | 2025 | Ogsiveo |
| Genentech USA, INC. | $88.45 | 2024-2025 | Polivy, Venclexta, Tecentriq |
| Eisai INC. | $84.13 | 2024-2025 | |
| Astellas Pharma US INC | $81.59 | 2024-2025 | Padcev, Vyloy, Xospata |
| Genmab U.S., INC. | $71.96 | 2024-2025 | Epkinly |
| Puma Biotechnology, INC. | $70.13 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $66.60 | 2024-2025 | Onivyde |
| Glaxosmithkline, LLC. | $62.58 | 2024-2025 | Ojjaara |
| Pharmaessentia USA Corporation | $58.71 | 2025 | Besremi |
| Iovance Biotherapeutics, INC. | $57.65 | 2025 | Amtagvi |
| Daiichi Sankyo INC. | $55.40 | 2024 | Enhertu, Injectafer |
| Beone Medicines USA, INC. | $52.23 | 2025 | Brukinsa |
| Exelixis INC. | $48.89 | 2024-2025 | Cabometyx |
| Array Biopharma INC | $47.21 | 2025 | Xalkori, Mektovi, Braftovi |
| Caris Mpi, INC. | $40.95 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $33.06 | 2024-2025 | Precisetumor, Myrisk |
| Tempus Ai, INC | $28.73 | 2024 | Xt Cdx |
| Taiho Oncology, INC. | $28.65 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.36 | 2025 | Givlaari |
| Tersera Therapeutics LLC | $25.52 | 2025 | Zoladex |
| Apellis Pharmaceuticals, INC. | $24.49 | 2024 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.38 | 2024 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $22.78 | 2024 | Ultomiris |
| Legend Biotech USA INC. | $21.34 | 2025 | Carvykti |
| Emd Serono, INC. | $20.75 | 2025 | |
| Syndax Pharmaceuticals, INC. | $18.57 | 2025 | |
| Gilead Sciences, INC. | $17.63 | 2024 | |
| Novocure INC. | $13.75 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Huggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.